Amyloid beta peptide N-terminal epitope (Aβ N-terminal epitope)

The N-terminal epitope of the Amyloid beta (Aβ) peptide is a primary pharmacological target for disease-modifying therapies in Alzheimer's disease (AD). Aβ is a proteolytic fragment of the Amyloid Precursor Protein (APP), produced through sequential cleavage by β-secretase and γ-secretase (UniProt P05067). While the physiological role of Aβ remains under investigation, its accumulation into soluble oligomers and insoluble fibrils is a hallmark of AD pathogenesis, leading to neurodegeneration and cognitive decline (Hardy & Higgins, 1992). The N-terminus, particularly residues 1–15, is highly immunogenic and solvent-exposed in various aggregated states, making it an ideal site for monoclonal antibody binding (Panza et al., 2019). Therapeutic agents like Aducanumab and Lecanemab bind to this region to promote the clearance of amyloid plaques via microglial-mediated phagocytosis and to neutralize toxic Aβ species (Sevigny et al., 2016; van Dyck et al., 2023). Clinical focus on this epitope has led to the first FDA-approved disease-modifying therapies for Alzheimer's, marking a significant milestone in neuropharmacology. Despite their efficacy in reducing plaque burden, drugs targeting this epitope are frequently associated with Amyloid-Related Imaging Abnormalities (ARIA), which represent a significant clinical safety challenge (Sperling et al., 2011). This epitope is also relevant in Cerebral Amyloid Angiopathy, where Aβ deposits in the walls of cerebral blood vessels.

Other names

Abeta N-terminusAβ1-15 regionAmyloid-beta N-terminal domainN-terminal Amyloid-beta epitopeAβ N-terminal fragment

Passive immunotherapy; antibody-mediated clearance of amyloid plaques via microglial phagocytosis; inhibition of Aβ aggregation and neutralization of soluble toxic oligomers.